Biobehavioral Markers May Improve Antidepressant Response in Major Depressive Disorder
Key Clinical Summary
- A prospective study evaluated biobehavioral markers to predict treatment response to the commonly prescribed antidepressants sertraline and bupropion in unmedicated patients with major depressive disorder (MDD).
- Patients with favorable biomarker profiles for 1 or both medications demonstrated higher response rates than those with negative markers for both drugs (71.4% or 65.4% vs 42.9%).
- Biomarker-consistent treatment assignment did not significantly improve outcomes compared with inconsistent drug assignment, although findings support further research into personalized antidepressant selection.
According to a prospective study published in Nature Mental Health, patients with MDD and favorable biobehavioral markers for sertraline and/or bupropion experienced higher antidepressant response rates than those with negative markers for both medications. However, assigning treatment based on these biomarkers did not significantly improve outcomes compared with biomarker-inconsistent treatment. The findings provide early evidence supporting further investigation of biomarker-informed approaches to personalized antidepressant therapy.
Study Findings
Researchers developed predictive algorithms using response markers for sertraline and bupropion derived from the Establishing Moderators and Biosignatures of Antidepressant Response in Clinical Care (EMBARC) multisite trial. Model performance during leave-one-out cross-validation was favorable, with area under the curve (AUC) values ranging from 0.66 to 0.86.
The algorithms were subsequently evaluated in an independent prospective clinical trial (SMART-D) involving unmedicated individuals with MDD. Investigators compared treatment outcomes, measured by Montgomery–Åsberg Depression Rating Scale (MADRS) score, among participants assigned to medications that were either consistent or inconsistent with their predicted biomarker profiles.
The trial did not identify significant differences in overall treatment outcomes between biomarker-consistent and biomarker-inconsistent treatment assignment (61.5%, 16/26) (X2 = 0.13, P = 0.72).
However, differences emerged when participants were stratified according to biomarker status. Patients with positive markers for both sertraline and bupropion achieved a 71.4% response rate, and those with positive markers for either medication had a 65.4% response rate. In contrast, participants with negative markers for both medications had a response rate of 42.9%.
The researchers reported a 66.8% boost in response rate, supporting further investigation of personalized treatment strategies for MDD.
Clinical Implications
The findings underscore both the promise and the current limitations of biomarker-guided antidepressant selection. Although assigning treatment based on biomarker predictions did not significantly improve outcomes in the prospective trial, biomarker-positive patients demonstrated substantially greater symptom improvement trajectories and response rates than those with unfavorable marker profiles.
For clinicians treating MDD, the study highlights the potential role of biobehavioral markers in identifying patients more likely to respond to specific antidepressants. Given the persistent challenge of low first-line treatment response rates, predictive tools could eventually help reduce trial-and-error prescribing and improve individualized care.
The authors emphasize, however, that these findings establish a foundation rather than definitive evidence for precision psychiatry. Larger prospective studies will be needed to determine whether biomarker-guided antidepressant selection can consistently improve clinical outcomes and be incorporated into routine practice.
Expert Commentary
“Our results suggest that we could boost response rate by using 2 sets of biomarkers previously identified in the EMBARC study, making an important contribution to advancing the goals of precision psychiatry,” wrote Peter Zhukovsky, PhD, Center for Addiction and Mental Health, Toronto, Ontario, Canada, and study coauthors.
“Ultimately, we strongly hope these advances will enable personalized treatment guidance to accelerate and boost antidepressant benefits,” they concluded.
